Japan’s OTC Market Rebounds On Brisk Lifestyle-Illness Drug Sales
This article was originally published in PharmAsia News
Executive Summary
TOKYO - While Japan's $70 billion pharmaceutical market is shrinking in value in line with the annual lowering of government health insurance drug prices, one sector is registering growth that industry officials describe as rather unexpected: the over-the-counter market for drugs that treat common colds to traditional Chinese medicines for metabolic syndrome
You may also be interested in...
Japan’s NHI-Claiming Pharmacy Numbers Rise
TOKYO - Amid a controversial plan to revamp a Japanese law on sales of prescription and OTC drugs, the number of pharmacies that dispense prescription drugs at the end of March 2007, or fiscal 2007, grew 1.1 percent over fiscal 2006 to 52,539, the Ministry of Health, Labor and Welfare reported Oct. 17
Japan’s NHI-Claiming Pharmacy Numbers Rise
TOKYO - Amid a controversial plan to revamp a Japanese law on sales of prescription and OTC drugs, the number of pharmacies that dispense prescription drugs at the end of March 2007, or fiscal 2007, grew 1.1 percent over fiscal 2006 to 52,539, the Ministry of Health, Labor and Welfare reported Oct. 17
Change In Japan’s OTC Laws Bodes Changes In Buying Habits
A major change in Japan's laws governing the sale of over-the-counter drugs is expected to lead to a major change in consumer buying habits when it takes effect next April. As of that month, supermarkets and other large retailers are to be allowed to sell OTC drugs, currently confined to pharmacies. A price battle between the two groups is expected to result from relaxation of the pharmaceutical affairs law, placing pressure on drugstores that have seen rapid growth recently, but now face a need to change business models. The law change would remove the current requirement that limits OTC drug sales to pharmacists, allowing regular sales staff to sell the drugs after a year of drug-selling experience and a "registered drug seller" license. (Click here for more - a subscription may be required